The National Health Service is issuing an urgent NHS call for Black blood donors as the demand for specialized blood products used to treat sickle cell disease has surged by more than 130% over the last decade. This spike in need has created a critical gap in the donor pool, leaving healthcare providers struggling to keep pace with the requirements of patients who need highly compatible blood to survive and maintain their quality of life.
Data from the NHS Blood and Transplant (NHSBT) service reveals that requests for haemoglobin S (HbS)-negative blood—the primary type used for sickle cell anaemia transfusions—rose from 82,181 units in 2015 to more than 191,000 units last year. This 132% increase reflects a growing patient population and a shift toward more intensive treatment protocols.
For the approximately 17,000 people living with sickle cell disorder across England, the availability of this specific blood type is not merely a preference but a clinical necessity. Because the condition primarily affects those from African and Caribbean backgrounds, the NHS is emphasizing that the most compatible matches are most likely to be found within these same communities.
The Clinical Necessity of HbS-Negative Blood
Sickle cell disease is a genetic condition where the body produces an abnormal form of haemoglobin known as haemoglobin S (HbS). As a physician, I often describe this to patients as a structural failure: while normal red blood cells are flexible discs that glide through capillaries, HbS causes cells to become rigid and crescent-shaped. These “sickled” cells can clog blood vessels, leading to severe pain, organ damage, and an increased risk of stroke.
When a patient requires a transfusion, receiving blood that also contains HbS can worsen these complications. Clinicians prioritize HbS-negative blood to ensure the transfused cells function normally and do not contribute to the blockage of blood vessels. Beyond the basic HbS-negative requirement, the clinical picture is further complicated by antibodies. Over time, many sickle cell patients develop antibodies against various blood antigens, meaning they require blood that is an exceptionally close match to their own to avoid transfusion reactions.
Chiara Vendramin of NHSBT noted that these antibodies can make finding compatible blood significantly harder, which can lead to dangerous delays in treatment. According to Vendramin, people from similar ethnic backgrounds are more likely to share the rare blood group types and antigens necessary for these complex matches.
A Stark Disparity in the Donor Pool
Despite the disproportionate impact of sickle cell disease on Black communities, the current donor statistics highlight a significant under-representation. While the NHSBT maintains a total of approximately 775,000 blood donors, only about 21,500 of those are of Black or mixed Black ethnicity.
| Donor Category | Approximate Number of Donors | Percentage of Total Pool |
|---|---|---|
| Total NHSBT Donors | 775,000 | 100% |
| Black or Mixed Black Donors | 21,500 | ~2.8% |
John James, chief executive of the Sickle Cell Society, has emphasized that these figures represent an “urgent need” for more donors from Black and brown heritage communities. To address this, the Society has partnered with the NHSBT to launch the “Give Blood, Spread Love” programme, an initiative designed to increase awareness and recruitment within under-represented groups.
James noted that giving blood is a simple act that can save or improve up to three lives, but for those battling sickle cell, it is frequently a life-saving intervention.
Why Demand is Accelerating
The 132% increase in blood requests is not attributed to a single cause, but rather a convergence of demographic and medical factors. Health officials point to an ageing population of sickle cell patients who are living longer thanks to better care, thereby requiring long-term transfusion support.
there has been an increase in the use of “exchange transfusions.” Unlike a standard transfusion, an exchange transfusion involves removing a patient’s existing blood and replacing it entirely with compatible donor blood. This process is used to rapidly reduce the percentage of sickled cells in the body, often to prevent a stroke or treat a severe crisis, but it consumes a far greater volume of units per patient.
NHSBT reports an increase in patients from geographic areas where sickle cell is more prevalent, further straining the existing supply of rare and compatible blood types.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for diagnosis and treatment of sickle cell disease or other medical conditions.
The NHSBT continues to seek donors with both common and rare blood types prevalent in the Black community to ensure no patient faces a delay in critical care. The service is focusing its current outreach on diversifying the donor base to match the evolving needs of the UK population.
We invite you to share this story to help spread awareness. If you are eligible, consider booking an appointment through the NHS Blood and Transplant app or website.
